Earlier this month, Pheno Therapeutics announced receipt of clinical trial authorisation in the UK for its lead multiple sclerosis (MS) therapeutic candidate PTD802, the first ever clinical trial ...

announced today it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.

A selective GPR17 (G protein-coupled receptor 17) antagonist, PTD802 is a novel small molecule therapeutic designed to promote remyelination. Developed under an exclusive worldwide licence ...

has cleared Pheno Therapeutics to initiate a first-in-human Phase 1 clinical trial to test its oral candidate PTD802 in healthy volunteers. The therapy is a selective small molecule antagonist ...

Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment for a common type of stroke; however, it did not lessen disability more than best medical ...

LONDON, Jan. 30, 2025 /PRNewswire/ -- LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three ...